SerpApi.Org
Financial derivatives exchange CME Group (NASDAQ:CME) reported Q2 CY2026 results , but sales were flat year on year at $1.71 billion. Its non-GAAP profit of $2.99 per share was 2.8% above analysts’ consensus estimates.
Is now the time to buy CME Group? Find out by accessing our full research report, it’s free.
CME Group (CME) Q2 CY2026 Highlights:
・Revenue: $1.71 billion vs analyst estimates of $1.68 billion (flat year on year, 1.7% beat)
・Pre-tax Profit: $1.33 billion (77.8% margin)
・Adjusted EPS: $2.99 vs analyst estimates of $2.91 (2.8% beat)
・Market Capitalization: $86.02 billion
Company Overview
Born from the Chicago Mercantile Exchange founded in 1898 as a butter and egg trading venue, CME Group (NASDAQ:CME) operates the world's largest derivatives marketplace where traders can buy and sell futures and options contracts across interest rates, equities, currencies, commodities, and more.
Revenue Growth
Examining a company’s long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. Luckily, CME Group’s revenue grew at a decent 8% compounded annual growth rate over the last five years. Its growth was slightly above the average financials company and shows its offerings resonate with customers.
Long-term growth is the most important, but within financials, a half-decade historical view may miss recent interest rate changes and market returns. CME Group’s annualized revenue growth of 8.1% over the last two years aligns with its five-year trend, suggesting its demand was stable.
Note: Quarters not shown were determined to be outliers because they were impacted by outsized investment gains/losses that are not indicative of the recurring fundamentals of the business.
This quarter, CME Group’s $1.71 billion of revenue was flat year on year but beat Wall Street’s estimates by 1.7%.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
Key Takeaways from CME Group’s Q2 Results
We were impressed by how much CME Group beat analysts’ EBITDA expectations this quarter. We were also happy its revenue outperformed Wall Street’s estimates. Overall, this print had some key positives. The stock traded up 1.4% to $240.33 immediately after reporting.
Is CME Group an attractive investment opportunity at the current price? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here (it’s free).
